Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Exec Urges Broader Debate on Japan’s CEA System
Japan’s upcoming technical discussions on its cost-effectiveness assessment (CEA) system should extend beyond methodological issues to cover broader structural problems with the framework itself, a senior industry official said on May 21. The comments come from Kenshi Kinoshita, director general…
To read the full story
Related Article
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
- Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
- Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
- Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
- Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
November 13, 2025
- Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
- Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
ORGANIZATION
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
- Incubator Led by Ex-Chugai CEO to Seek Govt Support, Raise Private Funds
June 30, 2026
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…